DE69331526D1 - Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel - Google Patents

Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel

Info

Publication number
DE69331526D1
DE69331526D1 DE69331526T DE69331526T DE69331526D1 DE 69331526 D1 DE69331526 D1 DE 69331526D1 DE 69331526 T DE69331526 T DE 69331526T DE 69331526 T DE69331526 T DE 69331526T DE 69331526 D1 DE69331526 D1 DE 69331526D1
Authority
DE
Germany
Prior art keywords
adenovirus
heart
guided
vascular muscle
smooth vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69331526T
Other languages
English (en)
Other versions
DE69331526T2 (de
Inventor
M Leiden
Eliav Barr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25525197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69331526(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arch Development Corp filed Critical Arch Development Corp
Publication of DE69331526D1 publication Critical patent/DE69331526D1/de
Application granted granted Critical
Publication of DE69331526T2 publication Critical patent/DE69331526T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
DE69331526T 1992-11-18 1993-11-16 Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel Expired - Fee Related DE69331526T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97749692A 1992-11-18 1992-11-18
PCT/US1993/011133 WO1994011506A1 (en) 1992-11-18 1993-11-16 Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle

Publications (2)

Publication Number Publication Date
DE69331526D1 true DE69331526D1 (de) 2002-03-14
DE69331526T2 DE69331526T2 (de) 2002-10-24

Family

ID=25525197

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69331526T Expired - Fee Related DE69331526T2 (de) 1992-11-18 1993-11-16 Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
DE69333886T Expired - Fee Related DE69333886T2 (de) 1992-11-18 1993-11-16 Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69333886T Expired - Fee Related DE69333886T2 (de) 1992-11-18 1993-11-16 Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel

Country Status (8)

Country Link
US (2) US6297220B1 (de)
EP (3) EP0957172B1 (de)
JP (4) JPH08506008A (de)
AT (2) ATE307212T1 (de)
AU (1) AU694097B2 (de)
CA (1) CA2149771A1 (de)
DE (2) DE69331526T2 (de)
WO (1) WO1994011506A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
AU727970B2 (en) * 1993-05-28 2001-01-04 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
AU7404994A (en) * 1993-07-30 1995-02-28 Regents Of The University Of California, The Endocardial infusion catheter
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
ES2249762T3 (es) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
FR2718150B1 (fr) 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
AU4502096A (en) * 1994-11-11 1996-06-06 Arch Development Corporation A process of inhibiting non-neoplastic pathological cell proliferation
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6306830B1 (en) 1996-09-05 2001-10-23 The Regents Of The University Of California Gene therapy for congestive heart failure
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5795872A (en) * 1995-09-19 1998-08-18 Pharmadigm, Inc. DNA construct for immunization
US7169764B1 (en) 1995-10-05 2007-01-30 Arch Development Corporation Promoter for smooth muscle cell expression
US6090618A (en) * 1996-10-07 2000-07-18 Arch Development Corporation DNA constructs and viral vectors comprising a smooth muscle promoter
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
EP0862644A2 (de) * 1995-11-17 1998-09-09 Franz, Wolfgang-M., Dr. Gentherapeutisches nukleinsäurekonstrukt, seine herstellung und verwendung zur behandlung von herzerkrankungen
US20010009904A1 (en) * 1997-12-30 2001-07-26 Jon A. Wolff Process of delivering a polynucleotide to a cell via the vascular system
WO1997029701A1 (en) 1996-02-15 1997-08-21 Biosense Inc. Catheter based surgery
DE69736862T2 (de) * 1996-07-17 2007-05-31 Medtronic, Inc., Minneapolis Abgabesystem zur Abgabe von genetischem Material an Herzgewebe
AU2437397A (en) 1996-07-17 1998-02-09 Medtronic, Inc. System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1998049300A2 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
US6775574B1 (en) * 1997-11-07 2004-08-10 Medtronic, Inc. Method and system for myocardial infarction repair
US6151525A (en) 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
US7031775B2 (en) 1997-11-07 2006-04-18 Medtronic, Inc. Method and system for myocardial infarction repair
EP1047784B2 (de) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Antigene aus neisseria meningitidis
US6309370B1 (en) 1998-02-05 2001-10-30 Biosense, Inc. Intracardiac drug delivery
AU767662B2 (en) 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
AU5819599A (en) 1998-09-11 2000-04-03 Regents Of The University Of California, The Recombinant adenovirus for tissue specific expression in heart
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP2975127A1 (de) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisseria antigenpeptide
AU2460001A (en) 1999-12-27 2001-07-09 Regents Of The University Of California, The Gene therapy for congestive heart failure
EP2275129A3 (de) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
EP1294407A2 (de) * 2000-06-30 2003-03-26 Collateral Therapeutics Zweirekombinante enthaltende zusammensetzungen zur gentherapie und verfahren zur herstellung
FR2811678B1 (fr) * 2000-07-12 2002-09-27 Inst Nat Sante Rech Med Promoteur specifique du myocarde
NZ518077A (en) 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
AU2001290273A1 (en) * 2000-10-06 2002-04-22 Dnavec Research Inc. Paramyxovirus vector for transferring foreign gene into skeletal muscle
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
JP2005501802A (ja) * 2001-01-23 2005-01-20 ボストン　サイエンティフィック　コーポレイション 虚血心筋を処置するための限局性心筋注入方法
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
EP1451306A1 (de) * 2001-11-06 2004-09-01 Medtronic, Inc. Verfahren und system zur operativen versorgung nach myokardinfarkt
EP2335723A1 (de) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen Chlamydia trachomatis
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US20040044329A1 (en) * 2002-08-29 2004-03-04 Trudell Leonard A. Catheter for cardiac injection and method for delivery of therapeutic agents to specified tissues
WO2004073484A2 (en) * 2003-02-24 2004-09-02 Yossi Gross Fully-implantable cardiac recovery system
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7818040B2 (en) * 2003-09-05 2010-10-19 Medtronic, Inc. Deflectable medical therapy delivery device having common lumen profile
CN1621094A (zh) * 2003-11-26 2005-06-01 犹太大学阿尔伯特爱因斯坦医学院 用于调节平滑肌张力的基因转移
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
CN104292321A (zh) 2004-03-29 2015-01-21 株式会社嘉尔药物 新的半乳凝素9 突变体蛋白质及其用途
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
ITRM20040569A1 (it) * 2004-11-18 2005-02-18 Biogem S C A R L Biotecnologie Modello animale per lo studio di sostanze ad attivita' cardioterapeutica ed anti-ipertensiva.
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US20070265221A1 (en) * 2006-05-09 2007-11-15 Weiss Robert G Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
WO2008103336A1 (en) * 2007-02-21 2008-08-28 Cook Incorporated Methods for intravascular engraftment in heart
CN101977632A (zh) * 2008-02-19 2011-02-16 塞拉东公司 用于增强病毒载体于心肌中的摄取的组合物
BR112019005144A2 (pt) * 2016-09-16 2019-06-04 Icahn School Med Mount Sinai sistema regulador de expressão, composição, métodos para expressar uma proteína, para induzir/reativar a proliferação de cardiomiócitos neonatais ou adultos e para expressar um gene de interesse, vetor, kit regulador de expressão, e, uso.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0456640A1 (de) 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetisch erzeugte endothelzellen und deren verwendung
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
SE464777B (sv) 1989-10-03 1991-06-10 Be Ge Ind Ab Progressiv luftfjaeder
IE20010427A1 (en) 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.

Also Published As

Publication number Publication date
WO1994011506A1 (en) 1994-05-26
JP2003102474A (ja) 2003-04-08
AU694097B2 (en) 1998-07-16
EP0957172B1 (de) 2005-10-19
EP0957172A3 (de) 2000-03-15
EP0668913A1 (de) 1995-08-30
US6436907B1 (en) 2002-08-20
DE69331526T2 (de) 2002-10-24
EP1321526A3 (de) 2003-07-02
JP2006212034A (ja) 2006-08-17
EP0957172A2 (de) 1999-11-17
DE69333886D1 (de) 2006-03-02
JP2004313198A (ja) 2004-11-11
EP1321526A2 (de) 2003-06-25
AU5609394A (en) 1994-06-08
EP0668913B1 (de) 2002-01-30
CA2149771A1 (en) 1994-05-26
JPH08506008A (ja) 1996-07-02
ATE212665T1 (de) 2002-02-15
US6297220B1 (en) 2001-10-02
ATE307212T1 (de) 2005-11-15
DE69333886T2 (de) 2006-07-27

Similar Documents

Publication Publication Date Title
DE69331526T2 (de) Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
GR3034094T3 (en) Viral recombinant vectors for expression in muscle cells.
DE69232983T2 (de) Adeno-assozierter virus 2 basalvektoren
DE69233010D1 (de) Universale spenderzellen
EP0092574A4 (de) Oligonukleotides heilmittel und dessen herstellungsverfahren.
FI955552A0 (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
DE69032284D1 (de) Expression von exogenen polynukleotidsequenzen in wirbeltieren
EP0935001A4 (de) Neuartige vegf-ähnliche faktoren
IL74947A (en) Analogs of human gamma interferon having the partial sequence of human gamma interferon and genetic engineering process for the preparation thereof
GR3025493T3 (en) Bystander effect tumoricidal therapy.
HUP0002913A2 (hu) Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára
MY101718A (en) Medicated cosmetic compositions
Schjerling The basics of gene doping
IL192893A0 (en) Cell-based gene therapy for the pulmonary system
DK0555785T3 (da) Glat-muskel-mitogent stof og DNA, der koder herfor
Paçarizi et al. The expression of growth factors in human melanomas
周洁民 et al. Expression of Human Factor Ⅸ cDNA in Mice by Implants of Genetically Modified Skin Fibroblasts From a Hemophilia B Patient

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee